X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ADCOCK INGRAM (S. Africa) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   ADCOCK INGRAM
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ADCOCK INGRAM
Jun-14
NOVARTIS/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs758344-   
Low Rs579248-   
Sales per share (Unadj.) Rs228.4102.2-  
Earnings per share (Unadj.) Rs31.7-25.8-  
Cash flow per share (Unadj.) Rs32.8-21.3-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.180.2-  
Shares outstanding (eoy) m24.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.9 101.2%   
Avg P/E ratio x21.1-11.5 -183.4%  
P/CF ratio (eoy) x20.4-13.9 -147.3%  
Price / Book Value ratio x2.23.7 61.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,50549,921 33.1%   
No. of employees `0000.74.3 15.6%   
Total wages/salary Rs m1,4453,133 46.1%   
Avg. sales/employee Rs Th8,441.34,019.0 210.0%   
Avg. wages/employee Rs Th2,163.6729.8 296.5%   
Avg. net profit/employee Rs Th1,173.1-1,012.7 -115.8%   
INCOME DATA
Net Sales Rs m5,63917,254 32.7%  
Other income Rs m1,718121 1,422.2%   
Total revenues Rs m7,35717,374 42.3%   
Gross profit Rs m-63-2,990 2.1%  
Depreciation Rs m25745 3.4%   
Interest Rs m55467 11.8%   
Profit before tax Rs m1,575-4,081 -38.6%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792255 310.4%   
Profit after tax Rs m784-4,348 -18.0%  
Gross profit margin %-1.1-17.3 6.4%  
Effective tax rate %50.3-6.2 -804.2%   
Net profit margin %13.9-25.2 -55.1%  
BALANCE SHEET DATA
Current assets Rs m9,52212,637 75.3%   
Current liabilities Rs m3,2967,110 46.4%   
Net working cap to sales %110.432.0 344.7%  
Current ratio x2.91.8 162.5%  
Inventory Days Days37111 33.0%  
Debtors Days Days28124 22.9%  
Net fixed assets Rs m467,366 0.6%   
Share capital Rs m12380 154.0%   
"Free" reserves Rs m7,2130-   
Net worth Rs m7,33613,542 54.2%   
Long term debt Rs m04,759 0.0%   
Total assets Rs m11,10525,582 43.4%  
Interest coverage x29.5-7.7 -381.3%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.7 75.3%   
Return on assets %7.6-15.2 -49.8%  
Return on equity %10.7-32.1 -33.3%  
Return on capital %22.2-19.8 -112.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,5700-   
CASH FLOW
From Operations Rs m1,6101,473 109.3%  
From Investments Rs m687-452 -151.9%  
From Financial Activity Rs m-2,6774,319 -62.0%  
Net Cashflow Rs m-3805,340 -7.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.74 Rs / ZAR

Compare NOVARTIS With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: PANACEA BIOTECH  IPCA LABS  DIVIS LABORATORIES  LUPIN  SHASUN PHARMA  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 268 Points Higher(Closing)

After opening the day marginally higher, Indian share markets continued their momentum and ended their day on a positive note.

Related Views On News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 19, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS